A new paradigm for drug development

Abstract

In January, 2020, British pharmaceutical company Exscientia announced that its compound DSP-1181, which is intended to treat obsessive compulsive disorder, was starting a phase 1 clinical trial. DSP-1181 was created using an artificial intelligence (AI) platform to trawl through chemical libraries and identify the most relevant compounds. Reportedly, DSP-1181 is the first such drug to enter clinical trials.

Topics & Concepts